Therapeutic strategies in the management of patients with metastatic anaplastic thyroid cancer: Review of the current literature

Roberta Granata, Laura Locati, Lisa Licitra

Research output: Contribution to journalArticlepeer-review

Abstract

PURPOSE OF REVIEW: Anaplastic thyroid cancer (ATC) is a rare and deadly malignancy. There is a need to speed up and support clinical research. This review article focuses on the new molecules that have been developed for the treatment of this aggressive tumor. RECENT FINDINGS: Improvement in the knowledge of pathogenesis and genetics of ATC led to the development of a variety of new molecules that may be used to treat this disease. In summary, these molecules are proteasome inhibitors, Aurora kinase inhibitors, vascular targeting agents, and gene therapies. All these molecules demonstrated a potentially therapeutic activity in metastatic ATC. To date, the largest prospective randomized multicenter, open-label, trial was conducted with combretastatin-A4. SUMMARY: More efficient drugs need to be developed through multinational efforts.

Original languageEnglish
Pages (from-to)224-228
Number of pages5
JournalCurrent Opinion in Oncology
Volume25
Issue number3
DOIs
Publication statusPublished - May 2013

Keywords

  • metastatic ATC
  • molecular target
  • new therapies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Therapeutic strategies in the management of patients with metastatic anaplastic thyroid cancer: Review of the current literature'. Together they form a unique fingerprint.

Cite this